Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Background: Fragile X syndrome (FXS), the most common single-gene cause of intellectual disability and autism spectrum disorder (ASD), is caused by a >200-trinucleotide repeat expansion in the 5’ untranslated region of the fragile X mental retardation 1 (FMR1) gene. Individuals with FXS can p...

Full description

Bibliographic Details
Main Authors: Dejan B. Budimirovic, Kelli C. Dominick, Lidia V. Gabis, Maxwell Adams, Mathews Adera, Linda Huang, Pamela Ventola, Nicole R. Tartaglia, Elizabeth Berry-Kravis
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Pharmacology
Subjects:
OV101
gaboxadol
fragile X syndrome
FMR1
GABAA
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.757825/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.757825/full

Similar Items